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RNase L: Its Biological Roles and Regulation
Shu-Ling Liang , David Quirk and Aimin Zhou
Summary
20-50oligoadenylate-dependent ribonuclease L (RNase L) is one
of the key enzymes involved in the function of interferons (IFNs), a
family of cytokines participating in innate immunity against viruses
and other microbial pathogens. Upon binding with its activator, 50-
phosphorylated, 20-50 linked oligoadenylates (2-5A), RNase L
degrades single-stranded viral and cellular RNAs and thus plays
an important role in the antiviral and antiproliferative functions of
IFNs. In recent years, evidence has revealed that RNase L displays
a broad range of biological roles which are summarized in this
review.
Keywords Interferon; RNase L; antivirus; apoptosis; prostate
cancer.
INTRODUCTION
Interferons (IFNs) are a family of cytokines participating in
innate immunity against a wide range of viruses and other
microbial pathogens. IFNs also have anti-tumor activities due
to their antiproliferative, immunoregulatory and apoptotic
properties (1). The eﬀects of IFNs are largely mediated
through proteins encoded by IFN-stimulated genes (ISGs).
One well-studied ISG is RNase L, which is one of the key
enzymes in the IFN-induced 2-5A system. The 2-5A system
consists of two types of enzymes: 2-5A synthetases and RNase
L. IFNs induce a family of 2-5A synthetase genes. The 2-5A
synthetases require double-stranded RNA (dsRNA) for their
activities. After activation by dsRNA, which is frequently
produced during viral infection, 2-5A synthetases convert ATP
molecules to pyrophosphate and a series of unique, 50-
phosphorylated, 20-50 linked oligoadenylates known as 2-5A
with the general formula ppp(A20p50)nA (n 2). 2-5A binds
RNase L with high aﬃnity, converting it from its inactive,
monomeric state to a potent dimeric endoribonuclease,
resulting in degradation of single-stranded viral and cellular
RNAs (Fig. 1).
The cDNA of human 2-5A dependent RNase L gene
encodes an 84 kDa protein with 741 amino acids. The
structural and functional analysis of RNase L has revealed
that this enzyme consist of two parts; the N-terminal half of
RNase L functions as a repressor while the C-terminal half
contains ribonuclease activity. The N-terminus contains 9
ankyrin repeats, typical protein-protein interaction domains,
suggesting that RNase L may interact with other proteins.
Previously, it has been reported that a duplicated P-loop like
motif (GKT) in ankyrin repeats 7 and 8 is implicated in 2-5A
binding (2). However, recent crystallographic data suggest
that the 2-5A molecule directly interacts with ankyrin repeats
2-4. Reduction of 2-5A binding activity by disruption of two
GKT motifs may be due to a conformational change (3). The
C-terminal half of RNase L has a cysteine rich region with a
protein kinase homology although kinase activity of RNase L
has not been demonstrated to date. The kinase-like and
ribonuclease domains at the C-terminus of RNase L are
related to the Ire1 kinases/ribonucleases that function in the
unfolded protein response in organisms from yeast to humans
(Fig. 2). Recent evidence indicates that RNase L displays a
broad range of biological functions including antivirus,
apoptosis, antiproliferation, and pathogenesis of prostate
cancer.
MECHANISM OF ACTION
RNase L is believed to display its biological function
through regulating mRNA stability following IFN exposure.
Ribosomal and viral RNAs are reportedly the ﬁrst targets of
RNase L. Recent evidence has shown that RNase L plays an
important role in the stability of several gene products,
including IFN-induced genes such as ISG43, ISG15 (4) and
PKR (5) in RNase L null cells, MyoD mRNA in myocytes (6),
mitochondrial mRNAs in H9 lymphocytes (7) and mitochon-
drial DNA-encoded mRNA (mt-mRNA) in monensin-treated
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mouse embryonic ﬁbroblasts (MEFs) (8). Interestingly,
activated RNase L selectively targets viral RNA in intact cells
and the action is 2-5A level dependent (9). 2-5A activates
RNase L and subsequently cleaves single-stranded RNA,
resulting in inhibition of both viral replication and cellular
proliferation. However, in the absence of viral infection, the
sources of dsRNA and 2-5A necessary to activate 2-5A
synthetases and RNase-L remain obscure. Recently it has been
reported that RNase L is able to regulate gene expression by
interacting with another protein (10). Peltz’s group observed
that RNase L can interact with human translation termination
factor eRF3/GSPT1 to modulate the translation termination
process, resulting in regulation of gene expression. The results
outline a novel role for RNase L as a regulator of translation.
Figure 1. The 2-5A system.
Figure 2. Functional domains of RNase L.
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Another report argues that interaction between the androgen
receptor and RNase L mediates a cross-talk between the IFN
and androgen signaling pathways (11).
Most recently, Silverman’s group has demonstrated
that 2-5A activation of RNase L remarkably stimulates the
expression of genes that suppress virus replication and
prostate cancer (12). These genes include IFN-inducible
transcript 1/P56, IFN-inducible transcript 2/P54, IL-8, and
ISG15. 2-5A treatment also signiﬁcantly induced RNA
transcription of the macrophage inhibitory cytokine-1/non-
steroidal anti-inﬂammatory drug-activated gene-1, a TGF-b
superfamily member implicated as an apoptotic suppressor of
prostate cancer. However, the precise mechanism for the 2-5A
transcriptional eﬀects remains to be elucidated. It is possible
that 2-5A activated RNase L suppresses the expression of
inhibitory factors for certain genes, resulting in promoting a
potent transcriptional response. The 2-5A stimulation of gene
expression is apparently through the activation of JNK and
ERK. These ﬁndings, no doubt, open a door for the further
study of the 2-5A system.
REGULATION OF RNase L
2-5A is a series of oligoadenylates synthesized by 2-5A
synthetases activated by dsRNA. To activate RNase L, 2-5A
must be a trimer or higher with at least one (human) or two
(mouse) 50-phosphoryl groups. Natural 2-5A molecules are
very unstable and are degraded by a combination of 50-
phosphatase and 20,50-phosphodiesterase present in cells.
RNase L inhibitor (RLI) is a cellular protein. The expression
of RLI is not regulated by IFNs, but is induced by viruses and
dsRNA. Overexpression of RLI in the cells strongly inhibits
the 2-5A binding and nuclease activities of RNase L (13).
RNase L activity can be regulated at its protein level (14).
Phorbol-12-myristate-13-acetate (PMA) treatment of mouse
L929 ﬁbroblasts resulted in the rapid degradation of RNase L
in a dose and time-dependent manner. Cellular RNase L levels
were decreased to 40% of control levels after only 5 min of
exposure to PMA. Following PMA treatment for 1 h, RNase
L levels decreased to 18% of the pretreatment levels. Protein
kinase C and selective proteasome inhibitors completely
prevent PMA-induced degradation of RNase L, suggesting
the involvement of protein kinase C and an active proteasome.
ANTIVIRAL ACTIVITY OF RNase L
Activation of the 2-5A system by IFN and virally produced
dsRNA leads to the rapid destruction of RNA. Inhibition of
viral replication in the IFN-treated cell could be the result of
viral RNA destruction followed by death of the infected cell.
The most striking evidence linking the 2-5A system to speciﬁc
antiviral eﬀects includes 2-5A accumulation and RNase L
activation in virus-infected cells, antiviral eﬀects in cells
expressing 2-5A synthetase cDNA, and, through inhibition
of RNase L activity, enhanced virus production and reduction
of the antiviral eﬀects of IFN (2).
Picornaviridae is one family of viruses strongly inhibited by
the 2-5A system. Encephalomyocarditis virus (EMCV), a
representative of picornaviruses, is a single-stranded positive-
sense RNA virus. The most cogent evidence that the 2-5A
system mediates IFN function against viruses comes from
studies of this virus. Upon infection, the mRNA of the virus is
translated on cellular ribosomes into a polymerase which then
generates the negative strand and forms a double-stranded
RNA replication intermediate. dsRNA intermediates derived
from EMCV bind to and activate 2-5A synthetase in
interferon-treated cells. IFN-treated cells after EMCV infec-
tion showed an activated 2-5A system and rRNA cleavage
products characteristic of RNase L activity (16). Another
strategy to study the involvement of the 2-5A/RNase L system
in the antiviral activity of IFN is to use the 2-5A analog,
CH3Sp(A2p)2A2pp3OCH3, or a core 2-5A which lacks three
phosphate groups at the 50end. These bind to, but do not
activate RNase L (2, 17). Transfection of the analog into IFN-
treated, EMCV-infected murine L929 cells inhibited rRNA
cleavage and increased virus production by up to 10 fold.
Expression of a dominant negative truncated RNase L in
murine SVT2 cells blocks the rRNA cleavage and reduces
about 250-fold the anti-EMCV eﬀects of IFN compared
with the IFN-treated vector control cells (2). Interestingly,
overexpression of human wild-type RNase L in NIH 3T3
cells displayed a weak inhibition of viral replication in the
absence of IFN-a. However, protection against viral infection
was dramatically increased after treatment with a low dose of
IFN-a, indicating that a 2-5A synthetase is needed to
synthesize 2-5A for the activation of RNase L (18). The
RNase L knockout mice succumbed to EMCV infections
more rapidly than infected wild-type mice (19). RNase L
knockout mice treated with IFN prior to EMCV infection
also died several days earlier than wild-type mice with the
same treatment. However, IFN treatment extended survival
to EMCV infection of both the RNase L wild-type and
knockout mice, suggesting multiple and overlapping antiviral
pathways of IFN. RNase L has been shown to have antiviral
eﬀects on other viruses such as vesicular stomatitis virus,
vaccinia virus, HIV-1, West Nile virus, herpes simplex virus
(HSV), and SV40 (15).
Several viruses have evolved strategies to counteract the
antiviral activity of the 2-5A system. For example, vaccinia
virus E3L proteins sequester the dsRNA from 2-5A synthetase
(20) and reovirus S4 gene encodes a dsRNA-binding protein
s3 with the same function (21). During HIV-1 infection, the
level of RLI is increased in human T cells (22).
APOPTOTIC ACTIVITY OF RNase L
An infected cell undergoing apoptosis may represent an
antiviral mechanism that acts by rapidly eliminating the
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infected cell, thus preventing the release of viral progeny.
Ribonuclease activity frequently has been associated with
apoptosis. Increases in ribonuclease activity during metamor-
phosis, glucocorticoid treatment, irradiation, and viral infec-
tion have in some cases coincided with DNA fragmentation,
indicating a correlation with classic biochemical markers of
apoptosis. Many studies have associated the activation of the
2-5A system, RNA breakdown, or ribonuclease activation
with cell death or tissue regression.
Indeed, activation of RNase L has been shown to induce
apoptosis. Overexpression of RNase L by a recombinant
vaccinia virus causes death of mammalian cells with
morphological and biochemical characteristics of apoptosis.
Coexpression of 2-5A synthetase augments the event (23).
RNase L overexpression sensitizes cells to the induction of
apoptosis by staurosporine: a general inducer of apoptosis
although by unknown mechanisms. This ﬁnding suggests that
RNase L is involved in multiple pathways of apoptosis.
RNase L-null mice showed enlarged thymuses and reduced
levels of spontaneous apoptosis in both the thymus and
spleen, implicating RNase L in the development of immune
cells. In addition, thymocytes and MEF isolated from RNase
L-null mice were resistant to apoptosis induced by staur-
osporine and irradiation (19). Activation of RNase L by 2-
5A transfection into the cells results in speciﬁc 18S rRNA
cleavage and induction of apoptosis, as measured by
TUNEL and annexin V binding assays. In contrast, the
dimeric form of 2-5A, ppA2p5A, neither activates RNase L
nor induces apoptosis. Apoptosis in response to RNase L
activity is companied by cytochrome C release from
mitochondria. Induction of apoptosis by 2-5A can be
blocked with either the pancaspase inhibitor, Z-VAD-fmk,
or with the caspase 3 inhibitor, DEVD-fmk, suggesting the
involvement of caspase activation in RNase L-mediated
apoptotic pathway. Evidence also shows that overexpression
of Bcl-2 prevents apoptosis induced by RNase L activation
(24).
Activation of RNase L in cells results in cleavage of rRNA,
leading a cellular stress response and activation of the Jun
N-terminal kinases (JNK) pathway. 2-5A treatment activates
JNK as determined by Western blot assay for phospho-JNK
and phospho-c-Jun, a downstream target of JNK. Various
inhibitors of MAP kinase, such as p38 and ERK, do not aﬀect
apoptosis in response to RNase L activation. SP600125, a
competitive inhibitor of ATP binding to JNK and some other
kinases, is able to signiﬁcantly attenuate apoptosis induced by
2-5A. Furthermore, JNK17/7/JNK27/7 MEFs are resistant
to 2-5A induced apoptosis, suggesting that activation of
RNase L requires JNK for eﬃcient induction of apoptosis
(25). dsRNA, an intermediate product of viral infection, is
able to activate JNK. Activation of JNK by dsRNA is
greatly reduced in cells lacking RNaseL (26). However,
how RNase L mediates the activation of JNK remains to be
fully understood.
ROLE OF RNase L IN THE REGULATION OF CELL
PROLIFERATION
Introduction of 2-5A into cells results in an inhibition of
growth rates, suggesting a role of RNase L in anticellular
proliferation (27). Furthermore, RNase L and 2-5A synthetase
levels were reported to be elevated in growth arrested or
diﬀerentiated cells and reduced in rapidly dividing cells,
indicating RNase L is involved in the fundamental control
of cell proliferation and diﬀerentiation (28, 29). Cells
expressing a dominant negative RNase L are resistant to the
antiproliferative activity of IFN-a. Similar to the role of
RNase L in antiviral activity, overexpression of wild-type
RNase L has limited impact on cell growth in the absence of
IFN-a. However, the cells are exquisitely sensitive to the
antiproliferative eﬀect of IFN-a (18). Interestingly, without
IFN-a treatment, RNase L7/7MEF cells grew 1.6-fold faster
when compared to RNase Lþ/þ cells. RNase L regulation of
cell proliferation independent of IFN-a was not limited to a
speciﬁc cell type. The growth rate of bone marrow cells
isolated from RNase L7/7 mice was 1.73-fold faster than that
from RNase Lþ/þ in the presence of granulate macrophage
colony stimulating factor (GM-CSF) (Zhou et al., 2006,
unpublished results), suggesting that RNase L may also
mediate unknown pathways to regulate cell growth.
RNase L IN PROSTATE CANCER
RNase L has also been shown to have an impact on the
pathogenesis of prostate cancer. Recent ﬁndings from several
laboratories have supported the identiﬁcation of the RNase L
gene, RNASEL, as a strong candidate for the long sought after
hereditary prostate cancer 1 (HPC1) allele. Carcinoma of the
prostate is the second leading cause of cancer deaths in men
450 years of age and the most frequent visceral cancer in
males. Indeed, the American Cancer Society estimates that in
the US there will be 234,460 new cases and 27,350 deaths from
prostate cancer in 2006 (www.cancer.org).
The linkage of HPC1 to RNASEL implies that RNase L
directly or indirectly suppresses one of more steps in prostate
pathogenesis and/or metastasis. RNase L was initially
proposed to be a candidate tumor suppressor on the basis of
its involvement in the antiproliferative activity of IFN and on
the location of RNASEL at chromosome 1q25, a region
deleted or rearranged in some cancers (30). In addition, RNase
L was shown to be deﬁcient in a human hepatoma, HEPG2
cell line (31). However, the ﬁrst in vivo evidence implicating
RNase L as a tumor suppressor was the identiﬁcation of
RNASEL as the candidate for HPC1 (24).
Mutation screening and an association study of RNASEL
as a prostate cancer susceptible gene have identiﬁed three
major RNASEL germline variants: E265X, M1L and R462Q.
E265X is associated with poor prognosis in clinical features.
This mutation terminates translation within the 2-5A binding
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domain of RNase L, thus abolishing 2-5A binding ability (32).
The second mutation, M1L, occurred in the translational start
codon: a methionine to isoleucine missense mutation. E265X
or M1L carriers had half the level of RNase L activity as
compared with homozygous wildtype RNASEL family mem-
bers suggesting that both mutations were inactivating.
However, R462Q variant is implicated in up to 13% of
prostate cancer cases. Carrying one copy of R462Q variant
gene increased the risk of prostate cancer by about 1.5 fold,
while having two variant alleles doubled the risk (33). An
additional mutation in RNASEL, 471DAAAG, causing a
frame shift at codon 157 and a translation stop after 7
additional codons, was discovered by Rennert et al. in
Ashkenazi Jews at a relatively high frequency (4%) and in
the model human prostate cancer cell line, LNCaP (34).
Although a relationship between the RNASEL gene and
prostate cancer is established, much more work needs to be done
to show how commonly it causes or modiﬁes the clinical course
of the disease. A larger population, both with and without
strong family histories, and with and without prostate cancer
need to be studied to see how often mutations in the gene are
associated with the disease and to ﬁnd out how often mutations
occur in men without the disease. Furthermore, how RNase L
functions as a tumor suppressor in prostate cancer tumorigenesis
and/or metastasis remain largely unknown. To the best of our
knowledge, there exist several possible mechanisms by which
RNase L could function as an anti-tumor protein.
First, the prostate has been reported to be a host organ for
multiple viral infections, including the human polyoma JC virus
and HPV (35). Recent identiﬁcation of a novel gammaretrovirus
in prostate tumors of patients homozygous for R462Q
RNASEL variant provides a possibility that there may be a
close relationship between exogenous infection and cancer
development in genetically susceptible individuals (36). RNase
L is an established antiviral gene. Involvement of a viral
pathogen in prostate cancer development remains a possibility.
Second, RNase L has antiproliferative and proapoptotic
activities, which suggest that RNase L may have a tumor
suppressor function. The 2-5A system is involved in cellular
responses to several external stimuli that result in apoptosis.
After knock-down of RNase L by siRNA in DU145 cells, a
prostate cancer cell line, cells were resistant to TRAIL and
camptothecin induced apoptosis (37). These ﬁndings indicated
that RNase L is involved in an apoptotic signaling pathway in
prostate cancer cells.
ROLE OF RNase L IN OTHER CELLULAR FUNCTIONS
RNase L has been linked to chronic fatigue syndrome
(CFS). CFS is a debilitating and complex disorder, character-
ized by extreme fatigue, which is not improved by bed rest and
which may be aggravated by physical or mental activity. A
number of studies have revealed that the 2-5A system is
impaired in CFS patients. Full length RNase L is degraded in
peripheral blood mononuclear cells (PBMC) by unknown
proteases, probably by an elastase. The proteolysis of RNase
L produces two major fragments with molecular masses of 37
and 30 kDa. The 37 kDa fragment is from the N-terminus of
RNase L with the 2-5A binding site whereas the 30 kDa
fragment contains the ribonuclease site in the C-terminal end
(38). Intriguingly, pre-incubation of RNase L with active 2-5A
results in a signiﬁcant protection of the native 84 kDa RNase
L against cleavage by endogenous and puriﬁed proteases,
suggesting that dimerization of RNase L induced by active 2-
5A may produce a conformation that covers the proteolytic
sites (39). However, the clinical signiﬁcance of these truncated
forms of RNase L in CFS needs to be further investigated.
More interestingly, RNase L7/7 mice showed a delayed
rejection of skin allograft, arguing that RNase L may also
contribute to tumor rejection through the immune system (40).
CONCLUSION
The unique mode of regulation and its involvement in the
mechanism of IFN action have been the focus of RNase L
study in the past three decades. Studies on prostate cancer
genetics and pathogenesis are providing a new direction for
future studies on this intriguing, regulated nuclease. Further-
more, the roles of RNase L in the regulation of gene
expression, signaling transduction and apoptosis oﬀer a
possibility for RNase L as a therapeutic target.
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